ASMB - Assembly Biosciences, Inc.
| Previous Close | 15.61 |
| Open | 15.59 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 800 |
| Day's Range | 15.20 - 16.24 |
| 52 Week Range | 13.13 - 48.91 |
| Volume | 188,931 |
| Avg. Volume | 325,450 |
| Market Cap | 400.621M |
| Beta (3Y Monthly) | 0.84 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.98 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 52.00 |
- GlobeNewswire•3 days ago
Development Veteran Steven J. Knox Joins Assembly Biosciences as Senior Vice President, Clinical Development
Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that Steven J. Knox has joined the Company, as Senior Vice President, Clinical Development. Mr. Knox comes to Assembly from Gilead Sciences where he most recently served as Vice President, Clinical Research and was responsible for global development programs in inflammation and viral hepatitis.
- Motley Fool•10 days ago
Here's Why Assembly Biosciences Is Slipping Today
Mid-stage clinical trial results weren't what some investors were looking for.
- GlobeNewswire•13 days ago
Assembly Biosciences Presents Interim Data from Two Phase 2a Studies of ABI-H0731 in HBV-Infected Subjects in a Late-Breaker Oral Session at EASL 2019
Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, presented interim results from two Phase 2a clinical trials of ABI-H0731 (731), a novel antiviral in development for the treatment of chronic HBV infection. The data were presented during a late-breaker oral session on Saturday, April 13, 2019, at The International Liver Congress™(ILC), the Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria. The late-breaker abstract was also selected for inclusion in the ‘Best of ILC’ presentation as well as for press release coverage at ILC 2019.
- GlobeNewswire•15 days ago
Assembly Biosciences Presents Data Highlighting Next-Generation HBV Core Protein Inhibitors at EASL 2019
Phase 1a study of ABI-H2158 demonstrated safety, tolerability and achievement of target liver concentrations ABI-H3733 demonstrated enhanced potency in preclinical studies HBV.
- Motley Fool•24 days ago
4 Biotech Stocks With Major Catalysts in April
April's about to shower biopharma investors with important updates that could move these stocks.
- GlobeNewswire•last month
Assembly Biosciences Announces Multiple Abstracts Highlighting HBV Core Inhibitor Portfolio Accepted for Oral and Poster Presentations at EASL 2019
SAN FRANCISCO, March 27, 2019 -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B.
- GlobeNewswire•last month
Assembly Biosciences to Participate in the Jefferies 2019 HBV Summit
SAN FRANCISCO, March 13, 2019 -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B.
- Simply Wall St.•2 months ago
If You Had Bought Assembly Biosciences Stock Three Years Ago, You Could Pocket A 261% Gain Today
It hasn't been the best quarter for Assembly Biosciences, Inc. (NASDAQ:ASMB) shareholders, since the share price has fallen 19% in that time. But that doesn't undermine the rather lovely longer-termRead More...
- GlobeNewswire•2 months ago
Assembly Biosciences Reports Fourth Quarter and Year End 2018 Financial Results
SAN FRANCISCO, Feb. 28, 2019 -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus.
- Zacks•2 months ago
Generic-Drugs Outlook: Price Erosion to Hurt Near-Term Prospects
Generic-Drugs Outlook: Price Erosion to Hurt Near-Term Prospects
- GlobeNewswire•2 months ago
Market Trends Toward New Normal in Brighthouse Financial, BioMarin Pharmaceutical, EZCORP, Assembly Biosciences, A-Mark Precious Metals, and American Public Education — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Feb. 13, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors,.
- Zacks•3 months ago
Mylan (MYL) Jumps: Stock Rises 7.1%
Mylan (MYL) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
- Simply Wall St.•3 months ago
Assembly Biosciences, Inc. (NASDAQ:ASMB) Insiders Increased Their Holdings
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be remiss not to mention that insider sales have Read More...
- GlobeNewswire•4 months ago
Assembly Biosciences Announces Completion of Enrollment in Two Phase 2a Studies with ABI-H0731 for Chronic Hepatitis B Virus
The studies are ongoing, and the company anticipates reporting interim results from both studies during Q2 of 2019. “Completing patient enrollment in both of our first Phase 2 studies marks an important milestone for our ongoing HBV clinical program and brings the potential of a cure closer to the millions of patients suffering from this chronic disease,” said Derek Small, President and Chief Executive Officer. “The data from these studies will serve to inform the timelines of the HBV cure program as well as the design of future registrational studies.
- Insider Monkey•4 months ago
Here is What Hedge Funds Think About Assembly Biosciences Inc (ASMB)
Concerns over rising interest rates and expected further rate increases have hit several stocks hard since the end of the third quarter. NASDAQ and Russell 2000 indices are already in correction territory. More importantly, Russell 2000 ETF (IWM) underperformed the larger S&P 500 ETF (SPY) by about 4 percentage points in the first half of […]
- Zacks•5 months ago
Amphastar Pharmaceuticals (AMPH) Catches Eye: Stock Jumps 6.7%
Amphastar Pharmaceuticals (AMPH) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
- Simply Wall St.•5 months ago
Should You Worry About Assembly Biosciences Inc’s (NASDAQ:ASMB) CEO Pay?
Derek Small became the CEO of Assembly Biosciences Inc (NASDAQ:ASMB) in 2015. First, this article will compare CEO compensation with compensation at similar sized companies. Next, we’ll consider growth that Read More...
- GlobeNewswire•5 months ago
Assembly Biosciences Presents Final Results of Phase 1b Study of ABI-H0731 at 2018 AASLD
Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, presented final data from the Phase 1b study of ABI-H0731 in patients with chronic HBV at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting®), in San Francisco. “We are excited about our progress with ABI-H0731 and our deep pipeline of core inhibitors,” said Uri Lopatin, MD, Chief Medical Officer of Assembly Biosciences. ABI-H0731-101b study was a Phase 1b study designed to test multiple dose levels of ABI-H0731 monotherapy for 28 days in treatment-naïve HBV patients.
- Zacks•6 months ago
Assembly Biosciences (ASMB) Reports Q3 Loss, Tops Revenue Estimates
Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 14.71% and 33.40%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•6 months ago
Assembly Biosciences: 3Q Earnings Snapshot
On a per-share basis, the Carmel, Indiana-based company said it had a loss of 87 cents. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
- GlobeNewswire•6 months ago
Assembly Biosciences Announces Third Quarter 2018 Financial Results and Provides HBV Program Update
ABI-H0731 Phase 2a Clinical Trials Actively Enrolling Patients; Data Continues to be Anticipated in 1H 2019 ABI-H2158 Phase 1a Study Initiated ABI-H3733 Nominated as Third.
- Zacks•6 months ago
Analysts Estimate Assembly Biosciences (ASMB) to Report a Decline in Earnings: What to Look Out for
Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire•6 months ago
Assembly Biosciences Announces November Conference Participation
SAN FRANCISCO, Oct. 31, 2018 -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus.
- Benzinga•7 months ago
Recent Assembly Biosciences Weakness Provides Attractive Entry Point, B Riley FBR Says In Upgrade
Assembly Biosciences Inc (NASDAQ: ASMB ) shares have shed over one-fourth of their value since late September, creating an opportunity to buy the dip, B. Riley FBR said Monday. The Analyst Analyst Madhu ...
